Tuyo Health: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.tuyohealth.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.

1. 1

   “The following claims concerning compounded semaglutide and tirzepatide products appear on your website:”

2. 2

   ““Same active as Wegovy and Ozempic” “Same active ingredient as Zepbound and Mounjaro” “With compounded semaglutide, you get the same trusted active ingredient as in brand-name medications….””

3. 3

   “Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not.”

1. 1

   Letter issued

   September 2025

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

tuyohealth.com returned a live storefront on 2026-08-09, titled "Tuyo Health | Online Telehealth Clinic for ED, Weight Loss & More", carrying published prices and a payment integration, so the site was transacting at that check.

Read the three claims in order and you can watch a chemistry statement turn into a reputation statement. "Same active" is a fact about a molecule. "Same trusted active ingredient as in brand-name medications" borrows something the molecule does not carry: the trials, the approval file, the years of post-market reporting that made the brand-name product trusted in the first place. None of that follows the ingredient into a compounded vial. FDA's objection was to the impression of sameness, not to the medicine or the price, and the practical lesson for a price comparison is narrow but real — when a cheaper option leans on the brand's credibility rather than its own, you are being asked to price in something the seller has not actually bought.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Tuyo Health failed to respond.